Simultaneous multi-antibody staining in non-small cell lung cancer strengthens diagnostic accuracy especially in small tissue samples.
Histological subclassification of non-small cell lung cancer (NSCLC) has growing therapeutic impact. In advanced cancer stages tissue specimens are usually bioptically collected. These small samples are of extraordinary value since molecular analyses are gaining importance for targeted therapies. We...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2013-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3572034?pdf=render |
| _version_ | 1819051318487023616 |
|---|---|
| author | Gian Kayser Agnes Csanadi Claudia Otto Till Plönes Nicola Bittermann Justyna Rawluk Bernward Passlick Martin Werner |
| author_facet | Gian Kayser Agnes Csanadi Claudia Otto Till Plönes Nicola Bittermann Justyna Rawluk Bernward Passlick Martin Werner |
| author_sort | Gian Kayser |
| collection | DOAJ |
| description | Histological subclassification of non-small cell lung cancer (NSCLC) has growing therapeutic impact. In advanced cancer stages tissue specimens are usually bioptically collected. These small samples are of extraordinary value since molecular analyses are gaining importance for targeted therapies. We therefore studied the feasibility, diagnostic accuracy, economic and prognostic effects of a tissue sparing simultaneous multi-antibody assay for subclassification of NSCLC. Of 265 NSCLC patients tissue multi arrays (TMA) were constructed to simulate biopsy samples. TMAs were stained by a simultaneous bi-color multi-antibody assay consisting of TTF1, Vimentin, p63 and neuroendocrine markers (CD56, chromogranin A, synaptophysin). Classification was based mainly on the current proposal of the IASLC with a hierarchical decision tree for subclassification into adenocarcinoma (LAC), squamous cell carcinoma (SCC), large cell neuroendocrine carcinoma (LCNEC) and NSCLC not otherwise specified. Investigation of tumor heterogeneity showed an explicit lower variation for immunohistochemical analyses compared to conventional classification. Furthermore, survival analysis of our combined immunohistochemical classification revealed distinct separation of each entity's survival curve. This was statistically significant for therapeutically important subgroups (p = 0.045). As morphological and molecular cancer testing is emerging, our multi-antibody assay in combination with standardized classification delivers accurate and reliable separation of histomorphological diagnoses. Additionally, it permits clinically relevant subtyping of NSCLC including LCNEC. Our multi-antibody assay may therefore be of special value, especially in diagnosing small biopsies. It futher delivers substantial prognostic information with therapeutic consequences. Integration of immunohistochemical subtyping including investigation of neuroendocrine differentiation into standard histopathological classification of NSCLC must, therefore, be considered. |
| first_indexed | 2024-12-21T12:02:02Z |
| format | Article |
| id | doaj.art-b48506469dcb4ee492e2516d4ee00515 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-21T12:02:02Z |
| publishDate | 2013-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-b48506469dcb4ee492e2516d4ee005152022-12-21T19:04:48ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0182e5633310.1371/journal.pone.0056333Simultaneous multi-antibody staining in non-small cell lung cancer strengthens diagnostic accuracy especially in small tissue samples.Gian KayserAgnes CsanadiClaudia OttoTill PlönesNicola BittermannJustyna RawlukBernward PasslickMartin WernerHistological subclassification of non-small cell lung cancer (NSCLC) has growing therapeutic impact. In advanced cancer stages tissue specimens are usually bioptically collected. These small samples are of extraordinary value since molecular analyses are gaining importance for targeted therapies. We therefore studied the feasibility, diagnostic accuracy, economic and prognostic effects of a tissue sparing simultaneous multi-antibody assay for subclassification of NSCLC. Of 265 NSCLC patients tissue multi arrays (TMA) were constructed to simulate biopsy samples. TMAs were stained by a simultaneous bi-color multi-antibody assay consisting of TTF1, Vimentin, p63 and neuroendocrine markers (CD56, chromogranin A, synaptophysin). Classification was based mainly on the current proposal of the IASLC with a hierarchical decision tree for subclassification into adenocarcinoma (LAC), squamous cell carcinoma (SCC), large cell neuroendocrine carcinoma (LCNEC) and NSCLC not otherwise specified. Investigation of tumor heterogeneity showed an explicit lower variation for immunohistochemical analyses compared to conventional classification. Furthermore, survival analysis of our combined immunohistochemical classification revealed distinct separation of each entity's survival curve. This was statistically significant for therapeutically important subgroups (p = 0.045). As morphological and molecular cancer testing is emerging, our multi-antibody assay in combination with standardized classification delivers accurate and reliable separation of histomorphological diagnoses. Additionally, it permits clinically relevant subtyping of NSCLC including LCNEC. Our multi-antibody assay may therefore be of special value, especially in diagnosing small biopsies. It futher delivers substantial prognostic information with therapeutic consequences. Integration of immunohistochemical subtyping including investigation of neuroendocrine differentiation into standard histopathological classification of NSCLC must, therefore, be considered.http://europepmc.org/articles/PMC3572034?pdf=render |
| spellingShingle | Gian Kayser Agnes Csanadi Claudia Otto Till Plönes Nicola Bittermann Justyna Rawluk Bernward Passlick Martin Werner Simultaneous multi-antibody staining in non-small cell lung cancer strengthens diagnostic accuracy especially in small tissue samples. PLoS ONE |
| title | Simultaneous multi-antibody staining in non-small cell lung cancer strengthens diagnostic accuracy especially in small tissue samples. |
| title_full | Simultaneous multi-antibody staining in non-small cell lung cancer strengthens diagnostic accuracy especially in small tissue samples. |
| title_fullStr | Simultaneous multi-antibody staining in non-small cell lung cancer strengthens diagnostic accuracy especially in small tissue samples. |
| title_full_unstemmed | Simultaneous multi-antibody staining in non-small cell lung cancer strengthens diagnostic accuracy especially in small tissue samples. |
| title_short | Simultaneous multi-antibody staining in non-small cell lung cancer strengthens diagnostic accuracy especially in small tissue samples. |
| title_sort | simultaneous multi antibody staining in non small cell lung cancer strengthens diagnostic accuracy especially in small tissue samples |
| url | http://europepmc.org/articles/PMC3572034?pdf=render |
| work_keys_str_mv | AT giankayser simultaneousmultiantibodystaininginnonsmallcelllungcancerstrengthensdiagnosticaccuracyespeciallyinsmalltissuesamples AT agnescsanadi simultaneousmultiantibodystaininginnonsmallcelllungcancerstrengthensdiagnosticaccuracyespeciallyinsmalltissuesamples AT claudiaotto simultaneousmultiantibodystaininginnonsmallcelllungcancerstrengthensdiagnosticaccuracyespeciallyinsmalltissuesamples AT tillplones simultaneousmultiantibodystaininginnonsmallcelllungcancerstrengthensdiagnosticaccuracyespeciallyinsmalltissuesamples AT nicolabittermann simultaneousmultiantibodystaininginnonsmallcelllungcancerstrengthensdiagnosticaccuracyespeciallyinsmalltissuesamples AT justynarawluk simultaneousmultiantibodystaininginnonsmallcelllungcancerstrengthensdiagnosticaccuracyespeciallyinsmalltissuesamples AT bernwardpasslick simultaneousmultiantibodystaininginnonsmallcelllungcancerstrengthensdiagnosticaccuracyespeciallyinsmalltissuesamples AT martinwerner simultaneousmultiantibodystaininginnonsmallcelllungcancerstrengthensdiagnosticaccuracyespeciallyinsmalltissuesamples |